TOBINintel · Condition
PCOS & Hormonal Dysregulation
PCOS is approached as a metabolic–endocrine phenotype: androgen and insulin signaling, adipose inflammation, nutrient status and endocrine-active exposures are evaluated side by side.
Key points
- Gut bacteriome and bile-acid patterns are tracked as potential modifiers of androgen metabolism, framed explicitly as a hypothesis.
- Test to discuss: Total and free testosterone, SHBG, DHEAS
- Test to discuss: LH, FSH, AMH where indicated
- Test to discuss: Fasting insulin, glucose, HbA1c
- Test to discuss: Thyroid and prolactin to exclude mimics
- Test to discuss: Pelvic ultrasound per criteria
- Insulin-sensitizing dietary pattern
- Resistance training
- Reduce avoidable endocrine-active exposures
- Early metabolic screening in family history
Root-cause chain
B · Established causal · Insulin amplifies LH-driven theca-cell androgen synthesis and lowers SHBG.
I · Observational association · Cytokine signaling contributes to peripheral insulin resistance in PCOS cohorts.
T · Observational association · Cross-sectional studies report higher urinary bisphenol levels in PCOS; direction of effect is unresolved.
N · Randomized evidence · Small trials report improved ovulatory frequency with myo-inositol; effect sizes vary.
Protocols by lane
Evidence grade + regulatory statusFirst-line for menstrual regulation and hyperandrogenism.
Status: FDA-approved · Cautions: Thrombotic risk; contraindicated in migraine with aura, smoking over 35, prior VTE.
Higher live-birth rate than clomiphene in PCOS.
Status: Off-label · Cautions: Requires fertility monitoring; not for use in pregnancy.
Improves ovulatory function and metabolic markers.
Status: Lifestyle · Cautions: Avoid restrictive patterns in disordered-eating history.
Modest improvements in ovulation and insulin indices in small trials.
Status: Supplement · Cautions: GI upset; monitor glucose with concurrent insulin sensitizers.
Small trials report reduced free testosterone.
Status: Supplement · Cautions: Not adequate for significant hyperandrogenism.
Trials show no reliable improvement in live birth rate.
Status: Investigational · Cautions: Should not displace ovulation induction when pregnancy is the goal.
Monitoring
- Cycle regularity log
- Androgenic symptom score
- Metabolic panel every 6–12 months
Go deeper
iDetection of an exposure does not establish that it caused a disease. This platform separates exposure, association, plausible mechanism, clinical evidence and demonstrated causation.